PDL Community Bancorp Q4 EPS $(0.64) Down From $0.89 YoY

PDL Community Bancorp (NASDAQ:PDLB) reported quarterly losses of $(0.64) per share. This is a 171.91 percent decrease over earnings of $0.89 per share from the same period last year.

byMichael Horton

January 30, 2023

1 minute read

PDL Community Bancorp (NASDAQ:PDLB) reported quarterly losses of $(0.64) per share. This is a 171.91 percent decrease over earnings of $0.89 per share from the same period last year.

Himax Collaborates With Wentai Over Smart Workspace Solution

By Anusuya Lahiri

Today, 2:10 AM

Himax Technologies, Inc (NASDAQ:HIMX) collaborates with Wentai Technology to exhibit a smart office solution enabled by Himax WiseEye smart image…

HIMX

VBI Vaccines Announces Presentation Of Data From Ongoing Phase 2a Study Of VBI-1901 At The 2022 Society For Neuro-Oncology Annual Meeting

By Benzinga Newsdesk

Today, 2:10 AM

VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing

VBIV

Barclays Maintains Overweight on Booking Holdings, Lowers Price Target to $2270

By Benzinga Newsdesk

Today, 2:10 AM

Barclays analyst Mario Lu maintains Booking Holdings (NASDAQ:BKNG) with a Overweight and lowers the price target from $2390 to $2270.

BKNG

Oramed Pharma Reports Completion Of Patient Enrollment In Phase 2 Oral Insulin NASH Trial; Topline Results Expected H2’22

By Benzinga Newsdesk

Today, 2:10 AM

- Topline results expected H2 2022 - ORMD-0801 is the first oral insulin to be evaluated as a treatment for NASH - Currently no FDA approved therapy exists for NASH NEW YORK, March 16, 2022 /PRNewswire/ -- Oramed

ORMP

PDL Community Bancorp Q4 EPS $(0.64) Down From $0.89 YoY

Related Posts

Himax Collaborates With Wentai Over Smart Workspace Solution

VBI Vaccines Announces Presentation Of Data From Ongoing Phase 2a Study Of VBI-1901 At The 2022 Society For Neuro-Oncology Annual Meeting

Barclays Maintains Overweight on Booking Holdings, Lowers Price Target to $2270

Oramed Pharma Reports Completion Of Patient Enrollment In Phase 2 Oral Insulin NASH Trial; Topline Results Expected H2’22